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Mutations in the common gamma chain (γc, CD132, encoded by the IL2RG gene) can lead to B+T−NK− X-linked
severe combined immunodeficiency, as a consequence of unresponsiveness to γc-cytokines such as interleukins-2,
-7 and -15. Hypomorphic mutations in CD132 may cause combined immunodeficiencies with a variety of clinical
presentations. We analyzed peripheral blood mononuclear cells of a 6-year-old boy with normal lymphocyte
counts, who suffered from recurrent pneumonia and disseminated mollusca contagiosa. Since proliferative
responses of T cells and NK cells to γc -cytokines were severely impaired, we performed IL2RG gene analysis,
showing a heterozygous mutation in the presence of a single X-chromosome. Interestingly, an IL2RG reversion to
normal predominated in both naïve and antigen-primed CD8+ T cells and increased over time. Only the revertant
CD8+ T cells showed normal expression of CD132 and the various CD8+ T cell populations had a different T-cell
receptor repertoire. Finally, a fraction of γδ+ T cells and differentiated CD4+CD27− effector-memory T cells carried
the reversion, whereas NK or B cells were repeatedly negative. In conclusion, in a patient with a novel IL2RG
mutation, gene-reverted CD8+ T cells accumulated over time. Our data indicate that selective outgrowth of partic-
ular T-cell subsets may occur following reversion at the level of committed T progenitor cells.
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ABSTRACT
Introduction
Somatic mosaicism is defined as the presence of genetically
distinct populations of somatic cells in a given organism.1
Although somatic mosaicism is assumed to be frequently
masked, it can also result in major phenotypic changes and
reveal the expression of otherwise lethal genetic mutations.
Mosaicism can be caused by DNA mutations, epigenetic
alterations of DNA, chromosomal abnormalities and the
spontaneous reversion of inherited mutations. Like somatic
mosaicism due to de novo mutations during embryogenesis,
mosaicism due to reversions to normal of an inherited muta-
tion have been discovered because of milder than expected
clinical courses and/or the presence of both phenotypically
normal and abnormal cells in vivo and in vitro.2 In the case of
spontaneous reversion, the mutation that has reverted to nor-
mal in some cells has been inherited from a parent.
Establishment of significant somatic mosaicism following
reversion to normal could modify disorders in which rever-
tant cells have a selective advantage in vivo. The rate of cell
turnover may be a factor that contributes to the chance of
spontaneous reversion as such. Most spontaneous reversions
have been found to occur in severe skin disease and hemato-
logic or immunological diseases.2-6 The growth advantage of
revertant cells has been the central dogma for the success of
gene therapy in severe combined immunodeficiency
(SCID).7,8
SCID is a collection of various gene defects that result in
the absence of T lymphocytes with or without the involve-
ment of B cells and/or NK cells.9 To date, spontaneous gene
reversions have been reported in several patients suffering
from ADA-SCID.10-14 This form of SCID that causes a meta-
bolic disease is due to defective adenine deaminase (ADA)
activity in all cells. It has been found that lymphocytes are
particularly sensitive to the toxic effects of the accumulating
purine metabolites in ADA deficiency. Reversed mutations
have also been found in patients with Wiskott-Aldrich syn-
drome15-17 and other primary T-cell immunodeficiencies such
as those caused by mutations in CD3zeta, RAG-1, LAD and
NEMO.5,18-21 The most common type of SCID in humans
shows X-linked inheritance and is caused by mutations in the
IL2RG gene.22,23 This gene encodes an essential subunit, the
common γ-chain (γc, CD132), of a cytokine receptor subfami-
ly that is essential for lymphocyte development, T-cell home-
ostasis, and peripheral immune responses.24 To date, only
three examples of gene reversion of an inherited mutation
have been reported in X-linked SCID and in all three cases
were in the common T-cell precursors, hence resulting in
reverted CD4+ and CD8+ T cells of both the TcRαb and TcRγδ
signature.25-27
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CD132 is a type I transmembrane glycoprotein that
serves as a subunit for the receptors (R) of interleukin (IL)-
2, IL-4, IL-7, IL-9, IL-15 and IL-21. The IL-2R and IL-15R
are heterotrimers consisting of unique α-chains and shared
IL-2Rb (CD122) and the CD132 subunit, whereas the IL-
4R, IL-7R, IL-9R, and IL-21R are heterodimers of unique α-
subunits and CD132. For each of the receptors CD132
contributes to ligand binding affinity, but also to signal
transduction through the direct association of Jak-3 to its
cytoplasmic tail.22-24,28 Mutations in CD132 abolish the
function in each of these cytokine receptors, resulting in
the absence or diminished numbers of T and NK cells,
while B-cell development is normal. X-SCID is diagnosed
early in life, but some exceptional cases and families have
been reported in which CD132 mutations resulted in an
immunological phenotype distinct from classical X-
SCID.29-34 These so-called X-CID (combined immune defi-
ciency) patients may have impaired rather than absent
function of CD132. Mosaicism due to somatic gene rever-
sion has been observed in the immune system as well as
in various other disease entities.1-6,17,35-37
Here we report a novel X-(S)CID family with a unique
mutation in the extracellular part of CD132.
Design and Methods
Additional details on the design and methods of this study are
provided in the Online Supplement.
Samples
Heparinized peripheral blood samples were collected from the
patient longitudinally. Peripheral blood mononuclear cells (PBMC)
were isolated using standard density gradient centrifugation tech-
niques and in some instances cryopreserved until use. The
patient’s samples were analyzed simultaneously with PBMC
obtained from healthy (age-matched) control donors. All partici-
pants provided written consent after being fully informed about
the study. The study was approved by the Medical Ethical
Committee of the Academic Medical Center in Amsterdam which
acts according to the principles of the Declaration of Helsinki (ver-
sion Seoul 2008).
Immunofluorescent staining and flow cytometry 
Absolute numbers of T cells, B cells and NK cells were deter-
mined in whole blood with Multitest six-color reagents (BD
Biosciences, Erembodegem, Belgium). For analysis of isolated
PBMC, cells were resuspended in phosphate buffered saline (PBS),
containing bovine serum albumin - sodium azide and incubated
with fluorescently labeled conjugated monoclonal antibodies. 
Proliferation assays
PBMC were resuspended in PBS, labeled with of 5,6-carboxy-
fluorescein diacetate succinimidyl ester (CFSE) in PBS, washed and
resuspended in culture medium and subsequently cultured for 6
days. T cells were stimulated with anti-CD3 with or without anti-
CD28 monoclonal antibodies and/or with specific cytokines at an
optimal dose for control cells. For antigen-specific CD4+ T-cell
stimulation tetanus toxoid, cytomegalovirus (CMV), varicella-
zoster virus (VZV) and Candida albicans antigens were used. For B-
cell proliferation, cells were stimulated with different combina-
tions of anti-IgM, anti-CD40, IL-21, CpG ODN 2006 and IL-2.
Supernatants were tested for secreted IgM and IgG with an in-
house enzyme-linked immunosorbent assay.38
IL2RG gene sequence analysis 
Genomic DNA was isolated from total peripheral blood leuko-
cytes and sorted subsets of lymphocytes.39 The coding exons of
the IL2RG gene (NCBI NM_000206) were amplified by poly-
merase chain reaction and sequenced using the BigDye
Terminator v1.1 cycle sequencing kit and a 3130 genetic analyzer
(Applied Biosystems). Short tandem repeats were analyzed with
the PowerPlex16 kit (Promega, Madison, WI, USA).40
T-cell receptor repertoire analysis by high throughput
sequencing 
The T-cell receptor repertoire of sorted cell populations was
analyzed as previously described.41,42 The complementarity deter-
mining region (CDR)-3 of the TCR-b-chain was used as a clonal
tag to identify individual clones. Briefly, mRNA was isolated and
cDNA was synthesized. In the first step of linear amplification
cDNA was amplified using a modified version of the Vb primerset
described by Dongen et al.43 All V-primers were tailed with the
primerB sequence needed for sequencing according to the 454
Titanium protocol for Amplicon sequencing (Roche Diagnostics,
Mannheim, Germany). In this article we use the HUGO nomen-
clature according to Folch and Lefranc.44 After linear amplification
a generic polymerase chain reaction was performed to prepare the
samples for sequencing. Over 40,000 (bead-bound) TCR
sequences were analyzed. 
Results
These studies were performed to diagnose and further
elucidate the molecular mechanisms of disease of a male
patient, the off-spring of non-consanguineous parents,
who was repeatedly admitted to the pediatric pulmonolo-
gy department because of infectious diseases. The initial
immunological screening did not point in the direction of
any immunological diagnosis and the humoral immune
response to vaccination was positive. 
When the patient was brought to our attention at the
age of 6 years, two notable findings were suspicious. First,
the mother’s twin brother had died at the age of 14 years
from an unexplained disease with liver failure and pro-
gressive bronchiectasis. He had been diagnosed at that
time with acrodermatitis eczematicum in the presence of
a low serum zinc and/or a less penetrant form of cystic
fibrosis, which could not be diagnosed at the DNA level
back then. Secondly, the index case was covered with
molluscum contagiosum virus lesions, which had not
resolved after 3 years. 
We repeated serological tests and found a complete
absence of antibodies against the standard immunizations
that the patient had received in the past [including
measles-mumps-rubella (MMR), diphtheria toxoid-
tetanus toxoid-inactivated pertussis polio virus vaccines].
Epstein-Barr virus (EBV) and CMV titers were screened as
well as VZV serology since the boy had suffered from
mild chickenpox in the past. All serological tests were neg-
ative in the presence of normal total values of IgG (12.6
g/L), IgA (0.58 g/L) and IgM (0.89 g/L). Upon repeating the
vaccinations against pneumococcal polysaccharides (PPS;
23-valent Pneumovax), tetanus toxoid and MMR, we
observed normal induction of antibodies. However, upon
follow-up the antibodies had completely disappeared
within 2-4 months to undetectable levels again. 
High resolution computed tomography scanning
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showed the presence of bronchiectasis. Cystic fibrosis
was excluded at the DNA level, zinc levels were normal,
other liver/lung diseases were excluded, including α1-
antitrypsin deficiency and primary ciliary disease. The
patient was put on monthly infusions of intravenous
immunoglobulins and co-trimoxazole prophylaxis. His
skin was enucleated in a 3-hour course of “peeling”, but
molluscum contagiosum lesions returned and disseminat-
ed again. During follow-up the clinical course improved
considerably. Over the last 7 years he has suffered only
once from an atypical pneumonia caused by Mycoplasma
pneumoniae, which responded favorably to macrolide
antibiotics and after several years his molluscum contagio-
sum started to disappear spontaneously.
Lymphocyte counts and subsets
As indicated by the absolute lymphocyte counts, all sub-
sets were in the low-normal range and remained stable
apart from the absolute numbers of CD8+ T cells which
increased over time and reached very high numbers result-
ing in an inverted CD4/CD8 ratio (Figure 1A). T-cell sub-
set analysis showed decreased percentages of naïve
(CD45RA+CD27+) CD4+ and CD8+ T cells for age con-
comitant with increased percentages of memory T cells
(CD45RA−CD27+), especially in the CD8+ T-cell subset
(Figure 1B). This disturbed CD8+ T-cell differentiation pro-
gressed over the years (Online Supplementary Figure S1),
whereas little change was seen in CD4+ T-cell differentia-
tion. TREC levels in CD3-sorted T cells were within the
normal range (data not shown). In the circulating B-cell frac-
tion, there was a notable lack of switched-memory B cells
with the IgD−CD27+ phenotype (<2% over time; normal
age-matched range, 6-15%) (Figure 1B).
Lymphocyte proliferation tests and cytokine 
receptor expression
We tested the patient’s CD4+ and CD8+ T cells for
αCD3/αCD28-mediated proliferation using CFSE dilution
and this was completely normal; almost all T cells under-
went several rounds of division (Figure 2A). The antigen-
specific memory responses were defined by assessment of
T-cell responsiveness against CMV, VZV, tetanus toxoid
and Candida albicans. Although the boy had been fre-
quently boosted with tetanus toxoid, had been infected by
chickenpox in the past, and must have been colonized by
Candida albicans before, no appropriate reaction to these
stimuli could be detected (Figure 2B).
Finally, we tested the proliferative responses of T and
NK cells toward the CD132 cytokines IL-2, IL-15 and IL-7
(Figure 2C and data not shown). Proliferation of NK and T
cells, especially CD4+ T cells, was diminished compared to
that of control cells. Cytokine titration curves also showed
that CD4+ T-cell responses were more severely affected
than CD8+ T-cell proliferation at different concentrations
(Online Supplementary Figure S2). 
The proliferative capacity of the boy’s B cells and simul-
taneous differentiation into CD20lowCD38high plasma cells
was analyzed using BCR-independent B-cell stimulation
with CpG. B-cell proliferation was normal but CD132-
dependent IL-2 signaling had no additional effect as
observed in cells from control donors (Online
Supplementary Figure S3). A similar defect was found when
B cells were activated via the BCR by a combination of
αIgM and αCD40 monoclonal antibodies in the absence
or presence of IL-21, again the patient’s cells did not
respond to the extra cytokine signal. Interestingly, the
patient’s B cells did not show any proliferation in response
to indirect activation via the agonistic αCD3/αCD28 mon-
oclonal antibody combination for T-cell stimulation
(Online Supplementary Figure S3, lower panels), as demon-
strated before in another X-linked CID case34. Together
these data show that the patient’s B cells are unresponsive
to common γ chain cytokines. The culture supernatants
were analyzed for in vitro IgM and IgG synthesis, which
was absent and hence indicated defective maturation into
Ig-secreting cells, irrespective of BCR-dependent or BCR-
independent activation (data not shown).
Family history, X-chromosome inactivation 
and IL2RG gene analysis
The family history indicated an X-linked pattern of
inheritance (Figure 3A). The X-linked nature of this
immunodeficiency was further supported by studies in
the obligate carriers [mother (II:1) and grandmother (I:2)],
demonstrating 100% skewing in X-inactivation in memo-
ry CD4+ and CD8+ T cells (data not shown). The mother’s
sister (II:4) delivered an affected male during follow-up.
He had normal numbers and percentages of CD4+ and
CD8+ T cells, B cells and NK cells, normal CD4/CD8 ratio
(1:1) and almost all T cells had a naïve phenotype as
expected in a neonate (CD4+ T cells 92%, CD8+ T cells
81% naïve). However, γc-cytokine induced proliferation
of T and NK cells was strongly diminished.  
Mutation analysis of the IL2RG gene was performed on
DNA isolated from total leukocytes of the index patient
and showed a single nucleotide substitution (c.655A>T)
representing a missense mutation resulting in a change at
amino acid position 219 from a tyrosine into an asparagine
residue (p.Tyr219Asn). In addition to the mutated allele, a
wild-type allele was detected, although at a lower fre-
quency.
The boy had no stigmata of Klinefelter disease (XXY)
which could explain the presence of two alleles. An alter-
native explanation for this genetic finding was the pres-
ence of circulating maternal T cells. However, this was for-
mally excluded by HLA-genotyping and short tandem
repeat marker analysis. We, therefore, concluded that the
wild-type allele originated from somatic reversion. To
determine in which lymphocyte subpopulation the
reversed wild-type allele was present, patient’s CD19+ B
cells, CD3−CD16/56+ NK cells and CD3+ T cells were sort-
ed from peripheral blood followed by sequence analysis.
In T cells the mutated and the reversed wild-type IL2RG
allele were detected with a similar frequency, whereas in
B and NK cells only the mutated allele was present (Figure
3B). In summary, the patient had a missense mutation in
the ILR2G gene that had reverted to a wild-type allele in
approximately half of the T cells.
IL2RG mutation analysis in sorted T-cell subsets
Over the years the number of CD8+ T cells increased
and this increase was observed in the memory fraction
(Online Supplementary Figure S1). To determine in which T-
cell subset the reverted allele was present and whether
this influenced the observed changes over time in domi-
nance of the CD8+ T-cell subset, CD4+ and CD8+ naïve
(CD45RA+CD27+), memory (CD45RA−CD27+), and effec-
tor (CD45RA−CD27−) T cells were sorted and the frequen-
cy of reversion was determined at two time points (t=0
and t=2 years). In naïve CD4+ T cells only the non-revert-
T.W. Kuijpers et al.
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ed, mutated allele was detected at both time points, in
memory CD4+ T cells only a small percentage was revert-
ed (Online Supplementary Table S1). At the second time
point 40% of the usually small fraction of CD4+CD27−
effector T cells was found to contain the reverted allele
(Figure 3C). In contrast, the reverted allele was found in
5% of the naïve CD8+ T cells and in 25% of memory
CD8+ T cells, and over a period of 2 years, these values
rose to 40% of the naïve CD8+ T cells and 90% of memo-
ry CD8+ T cells. The effector CD8+ T cells had a reversion
frequency of 80% (t=2 years). Finally, in two additional
sorts from different time points, TCRγδ+ T cells were iso-
lated and in this T-cell population the reversion frequency
was stable at 20% (Online Supplementary Table S1). These
results show that the reverted allele was present in differ-
ent T-cell lineages, indicating a progenitor T cell as the
common source of the circulating revertant T cells. 
Properties of the CD8+ T-cell population
When the findings on partial gene reversion became
apparent, we tested for the expression of CD132 and clonal
composition in both the naïve and memory CD4+ and
CD8+ compartments. CD132 expression was tested after
activation of the PBMC for 3 days with αCD3/αCD28
monoclonal antibodies. In contrast to the very low CD132
expression on activated CD4+ T cells, CD132 expression
was clearly present on CD8+ T cells after stimulation
(Figure 4). The highest expression of CD132 was detected
on the CD27- memory-effector CD8+ T cells. CD132 was
not expressed on the patient’s B and NK cells. Expression
of CD25 and CD122 (the other chains of the IL-2 receptor)
was strongly up-regulated as normal on both activated
CD4+ and CD8+ T cells (data not shown). 
The patient’s TCR repertoire was suggested to be intact
by the normal variety found by flow cytometric analysis
using 24 Vb monoclonal antibodies covering about 80%
of Vb antigens on the patient’s T cells (data not shown).
Subsequent analysis of the sorted subsets of CD8+ T cells
from the patient was performed, showing a broad Vb
repertoire by monoclonal antibody staining in both the
sorted naïve (CD45RA+CD27+) as well as memory CD4+
and CD8+ T-cell subsets. 
Using subsequent high-throughput TCR-b sequencing,
we tested whether the expanded revertants would domi-
nate the memory repertoire by an oligoclonal signature.
Data from previous studies on clonality in the naïve and
memory compartments were used as a reference.41 By
sequencing >7000 individual TCR in the patient’s CD8+ T
cells, we found that the clonal distributions in the
CD8+CD45RA− (memory) subset and the
CD8+ T-cell advantage in reversed IL2RG mutation
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Figure 1. Increased numbers and disturbed differentiation of CD8+ T cells. (A) Absolute numbers of total and CD4+ and CD8+ T cells, CD4/CD8
ratio, CD3-CD56+ NK cells and CD19+ B cells. Dotted lines indicate upper and lower limits of normal for corresponding age (changing at age
10 years), for CD4/CD8 ratio only the lower limit of normal is shown. (B) Distribution of naïve, memory and effector-memory T cells in both
CD3+CD4+ and CD3+CD8+ T cells (i.e. CD45RA+CD27+, CD45RA−CD27+, CD45RA+or−CD27−, respectively), at 11 years of age compared to values
in a 10-year old healthy control. Lower panels: B-cell differentiation (naïve, non-switched or class-switched memory, i.e. sIgD+CD27−
sIgD+CD27+ or sIgD−CD27+). 
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CD8+CD45RA+CD27+ (naïve) T-cell subset were normal
when compared to those of healthy individuals, showing
no signs of oligoclonal signatures (Figure 5A). This was
further confirmed by the diverse use of the (variable)
genes of the TCR-b-chain (Figure 5B). This broad reper-
toire indicates that normal VDJ-rearrangement had taken
place in the naïve T-cell subset, which is similar to that of
healthy individuals. The non-revertant component may
T.W. Kuijpers et al.
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Figure 2. T-cell proliferation in response
to recall antigens and cytokines is
diminished. Analysis of proliferation of
healthy control and patient CFSE-
labeled cells after 6 days of culture with
the indicated stimuli. (A) Proliferation of
CD4+ and CD8+ T cells activated with
αCD3/αCD28 monoclonal antibodies.
(B) Proliferation of antigen-specific
CD4+ T cells to recall antigens. The
number indicate percentages of divided
cells minus the background in unstimu-
lated samples. (C) Proliferation of T
cells in response to CD132 cytokines IL-
2, IL-15 and IL-7. The number indicate
percentages of undivided cells. No stim
= unstimulated condition.
aCD3+
aCD28
CFSE
CFSE
no stim
no stim
no stim
IL-15
IL-7
IL-2
aCD3+
aCD28
no stim
Tetanus
Candida
VZV
CMV
control patient control patient
CD4+ T cells
CD4+ T cellsA B
C
CD4+ T cells
CD8+ T cells
CD8+ T cells
CFSE
CD
4
Nu
m
be
r o
f c
el
ls
Nu
m
be
r o
f c
el
ls
# 
ce
lls
Nu
m
be
r o
f c
el
ls
control patient
control patient
control patient
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104FL1-H: CFSE
FL
2H
: C
D4
 P
E
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
2000
1500
1000
500
0
15
10
5
0
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
1000
800
600
400
200
0
500
400
300
200
100
0
1000
800
600
400
200
0
200
150
100
50
0
120
90
60
30
0
2000
1500
1000
500
0
400
300
200
100
0
800
600
400
200
0
1500
1000
500
0
500
400
300
200
100
0
500
400
300
200
100
0
800
600
400
200
0
800
600
400
200
0
800
600
400
200
0
1000
800
600
400
200
0
200
150
100
50
0
1200
900
600
300
0
1500
1000
500
0
2500
2000
1500
1000
500
0
300
200
100
0
300
200
100
0
800
600
400
200
0
© 
Fe
rra
ta 
St
ort
i F
ou
nd
ati
on
. 
No
 co
mm
erc
ial
 us
e i
s a
llo
we
d
have contributed to the fully diversified repertoire of the
memory CD8 T+ cell subset but as this is a relatively small
fraction of the total cell population it seems unlikely that
the full diversity can be attributed to these cells. Thus, the
revertant populations were highly diverse in their TCR
repertoire and not oligoclonal in nature. 
Discussion
In this study we describe a novel family with non-clas-
sical X-(S)CID and a spontaneous reversion of the genetic
defect that was identified in some of the CD8+ T cells. The
patient was admitted with recurrent pulmonary infections
CD8+ T-cell advantage in reversed IL2RG mutation
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Figure 4. Decreased expression of CD132 on lymphocytes of the X-CID
patient. CD132 expression on lymphocyte subsets upon 3-day stimula-
tion using antiCD3/antiCD28 monoclonal antibodies. Filled histograms:
unstimulated cells, black line: activated cells.
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Figure 3. X-linked inheritance of the IL2RG gene locus and mutation analysis. (A) Pedigree of the family indicates the X-linked inheritance by
the index (III-2) who is alive and well, and the affected brother (II:2) who died from X-CID. The patient’s mother (II:1), one of her sisters (II:4),
and the grandmother (I:2) are carriers of the mutated IL2RG gene (circles with dots). (B) Gene sequence analysis is shown for the patient in
leukocytes, and sorted total T, B and NK cell subsets. Fifty percent of T cells had a reversion mutation (back mutation, indicated in red). (C)
Percentage reversion in T-cell subsets at t=2 years; (naïve CD45RA+CD27+, memory CD45RA-CD27+, effector CD45RA+/-CD27-). See also Online
Supplementary Table S1.
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and widely spread molluscum contagiosa virus lesions on
his skin. The X-linked pattern of inheritance combined
with a defect in cytokine-mediated T-cell proliferation led
to the identification of a missense mutation in the gene
coding for CD132 (IL2RG) (c.655A>T). 
This mutation has not been described before
(http://research.nhgri.nih.gov/scid/) and results in replacement
of tyrosine 219 by asparagine (p.Tyr219Asn) in the extra-
cellular domain. The amino acids of the linker region are
highly conserved in the mammalian CD132 protein, sug-
gesting a role in ligand binding as based on theoretical
grounds and epitope mapping studies with anti-human
CD132 antibodies. Outside the linker region the residues
p.Leu208 to p.Ser211 affect cytokine binding by conforma-
tion constraints on the two extracellular loops of CD132.45
Although not proven, the nearby p.Tyr219Asn substitution
may similarly affect the quaternary binding interaction of a
cytokine with its respective αbγ or αγ receptor complex.
The IL2RG mutation most likely acts as a hypomorphic
mutation because the non-reverted T and NK cells carrying
this mutation were normally detectable in peripheral
blood, thus not causing any lymphopenia in the patient. In
fact, the patient’s younger cousin who was born some
years later carried the same mutation in the absence of any
reversion, having normal cord blood lymphocyte counts.
However, CD132 expression was strongly reduced on his
peripheral blood lymphocytes and the cytokine-induced
proliferative responses of his T and NK cells were dimin-
ished. This also implies that initial immunological screen-
ing is not sufficient for the diagnosis of these types of
patients; only analysis of CD132 up-regulation together
with cytokine responsiveness can reveal the defect. 
Despite the relatively normal serology upon immuniza-
tion with various vaccines, the specific antibody titers
became undetectable again within the following weeks.
We observed a reduced number of CD27+ memory B cells
that persisted over the years. The patient had lost specific
antibodies against VZV and CMV, and virus-specific
memory CD4+ T cell reactivity was hardly detected,
emphasizing the need for γc signals for maintenance of
immunological memory. There was no lymphopenia but a
clear and progressive inversion of the CD4/CD8 ratio was
observed. Whereas CD132 expression by activated CD4+
T cells was diminished, on CD8+ T cells this was clearly
detectable upon cell activation. It is within this population
of CD8+ T cells that we had identified the reversion to pre-
dominate, which may have contributed to the proportion-
ally increased cell number in the blood counts.
To date, only three cases of IL2RG gene reversion have
been reported at the T-cell precursor stage.25-27 A reversion
of a specific deleterious point mutation is statistically
highly unlikely. However, in vivo selection could allow
such a rare event, because any reversion of the inherited
IL2RG mutation in T cells would confer a distinct advan-
tage, in terms of growth and differentiation, over cells
without functional CD132 chains. In our case, only partial
gene reversion was observed to be present in the T cells.
This could be explained by the hypomorphic nature of the
T.W. Kuijpers et al.
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Figure 5. TCR-b analysis in
reverted cells shows a
diverse repertoire. (A)
CD8+CD45RA− (memory)
subset and the
CD8+CD45RA+CD27+ (naïve)
were sorted using FACS
(>95% purity). Both samples
were prepared for high
throughput sequencing using
a primer set that covers the
complete TCR-b repertoire.
From both samples approxi-
mately 10,000 TCR-b
sequences were sequenced
using high throughput
sequencing. Each clone is
depicted as a dot showing its
relative frequency to the
complete subset (percent-
age of total reads). As a
comparison we used control
samples. (B) Vb-usage of the
same samples used in (A)
was determined. Use of V-
genes (and J-genes, data not
shown) was comparable to
that of healthy controls (data
not shown). 
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IL2RG mutation that still allowed T and NK cell develop-
ment to occur, which would fit with the delayed clinical
presentation. 
All reverted T cells in the patients reported thus far arose
from a single revertant T-cell precursor, as was confirmed
by the polyclonal T-cell repertoire.46 Also in our patient the
T cell repertoire was polyclonal. In addition, analysis of
TCRγδ+ T-cells showed that gene reversion was present in
part of the cells. The split in TCRγδ+ and TCRαb+ T-cell
differentiation occurs between the CD4−CD8− double-
negative and CD4+CD8+ double-positive thymocyte stage
of T-cell differentiation in the thymus. This implies that
the genetic reversion occurred in the thymus before or
during the double-negative stage, which reflects a stage of
T-cell differentiation that does not depend on any CD132
expression.24
A common theme is the selective survival advantage of
the revertant immune cells over mutant cells, which has
been amply discussed in terms of its implications for gene
therapy. Our data confirm the developmental potential of
a single T-cell precursor in humans with broadly diverse T-
cell repertoire.25,26 The mutations in these two cases also
predicted amino acid substitutions (p.Cys115Arg and
p.Leu151Pro) in the extracellular part of the protein,25,26 but
had – in contrast to our case – a more global T-cell pattern
of gene reversion. Importantly, although the reversion
must have occurred in a common T-cell progenitor, accu-
mulation of reverted cells was not found in either naïve or
memory CD4+ cells nor in the NK or B cells. This suggests
that for these populations the reversion offered no selec-
tive advantage, or at least a very minor one compared to
CD8+ T cells. In this respect, it is of interest to note that
the mutated receptor is not completely unable to signal
dead as CD4 T+ cells showed a low but detectable
response to cytokines such as IL7. The difference in the
amount of reversion between the CD4+ and CD8+ T-cell
pools suggests that in this patient, who has a partially
active common-gamma chain, the dependence on signal-
ing through this receptor differs between the two T-cell
populations. The small fraction of effector CD4+ T cells
(<2% of total CD4+ T cells), also carried the reversion in a
large part of the cells, which suggests that this T-cell sub-
set requires a fully functional CD132 to be generated or
persist in vivo. Whether these effector CD4+ T cells largely
reside in the tissues or have a shorter life span is unknown,
but the reversion did not result in an accumulation in the
circulation. Of course, the possibility remains that more
revertant CD4+ T cells will emerge over time in the case
the kinetics are just much slower than for CD8+ T cells.
This could be, for example, because of preferential anti-
gen-driven expansion of CD8+ T cells caused by chronic
infection. Another interesting finding was the high per-
centage of naïve CD8+ T cells carrying the reversion
(40%). This implies the persistence of reverted progenitor
T cells that continue to supply new revertant naive T cells
or a very long half-life of these naïve CD8+ T cells.  
In our patient the widely disseminated molluscum con-
tagiosum virus infection of the skin slowly but completely
cleared after many years, indicating improved cellular
immunity. Although the developmental stage of gene
reversion was not investigated, a similar effect of infec-
tion-driven proliferative advantage due to gene reversion
was recently suggested in XLP patients showing selective
expansion of reverted CD8+ T cells only, following EBV
infection.47
The preferential expansion of CD8+ reverted T cells
makes our X-SCID case unique and suggests a more
important role for CD132-signaling in proliferation
(homeostatic or antigen-driven) of CD8+ T cells as com-
pared to CD4+ T cells.48 The IL2RG gene reversion in the
polyclonal CD8+ T-cell outgrowth did not result in com-
plete recovery of all clinical symptoms demonstrating that
rescue of CD8+ T cells alone is not sufficient for full
restoration of immunity. 
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